Developer docs
API playgroundTry for free, no card

Search company profiles

Galectin Therapeutics

Full company profile

uuid0003mwd

Namestring
Galectin Therapeutics
Legal namestring
Galectin Therapeutics Inc.
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Galectin Therapeutics is a clinical-stage biopharmaceutical company founded in 2000 and listed on NASDAQ under the ticker GALT, headquartered in Norcross, Georgia (Delaware-incorporated). The company develops novel therapies targeting galectin proteins, with its lead drug candidate belapectin (GR-MD-02) — a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that binds and inhibits galectin-3 — being advanced primarily for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Belapectin is currently being evaluated in the NAVIGATE Phase 2b/3 clinical trial at approximately 130 sites across 12 countries, with Phase 2b results published in Hepatology in May 2026 and FDA alignment on a Phase 3 protocol achieved in June 2026; a Phase 3 protocol filing is planned for Q3 2026. The molecule carries FDA Fast Track designation and is protected by composition-of-matter, methods-of-use, and methods-of-production patents extending through at least 2035.

The company is pre-revenue with no commercialized products and is funded primarily by Chairman Richard E. Uihlein, who has provided approximately $100 million in convertible debt and credit facilities between 2021 and 2025, with the most recent December 2025 facility extending cash runway through at least March 2027. Beyond the MASH cirrhosis lead indication, Galectin Therapeutics runs exploratory programs in cancer immunotherapy (combination trials with KEYTRUDA and Yervoy showing a 50% objective response rate in advanced melanoma versus 33% for KEYTRUDA alone), psoriasis (Phase 2a), and atopic dermatitis, all of which the company intends to out-license. Discovery efforts include Galectin Sciences, a collaboration with SBH Sciences to develop oral small-molecule galectin inhibitors, and academic collaborations with the University of Georgia and University of Minnesota.

Galectin's go-to-market model is enterprise-biopharma: the company runs an international Phase 2b/3 trial via Covance as CRO, pursues FDA regulatory alignment, and intends to seek large-pharma co-development and commercialization partnerships for belapectin upon Phase 3 progression. The addressable market is large — over 115 million people worldwide have MASH, and the MASH treatment market is projected to reach $8.6 billion by 2030 at a 22% CAGR. The company has 11–50 employees, presents at investor and scientific conferences (H.C. Wainwright, AASLD, EASL), and publishes in peer-reviewed journals to support both investor positioning and clinical credibility.

Short descriptiontext

Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin (GR-MD-02), a proprietary galectin-3 inhibitor, primarily for MASH cirrhosis patients at risk of esophageal varices, with exploratory programs in cancer immunotherapy, psoriasis, and atopic dermatitis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorcross, United States
HQ citystring
Norcross
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
galectin-3 inhibitors, MASH cirrhosis therapeutics, carbohydrate-based drugs, fibrotic disease treatment, cancer immunotherapy combinations
Industry2 codes
PRIMARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
Product category
MASH cirrhosis biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development / Future Product Revenue
TypeOne Time License
Description

Pre-revenue clinical stage company. The company is developing belapectin for MASH cirrhosis and cancer immunotherapy. Revenue would be generated through future product sales following regulatory approval. The company also seeks partners as programs advance requiring greater resources.

galectintherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Galectin Therapeutics is developing belapectin (GR-MD-02), a proprietary carbohydrate-based galectin-3 inhibitor, as a disease-modifying therapy for MASH cirrhosis and portal hypertension. The company runs the NAVIGATE Phase 2b/3 clinical program across approximately 130 sites in 12 countries and pursues additional exploratory programs combining belapectin with checkpoint inhibitors (KEYTRUDA, Yervoy) in advanced melanoma and head and neck cancer, as well as in psoriasis and atopic dermatitis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 50% objective response rate in advanced melanoma with belapectin + KEYTRUDA vs 33% for KEYTRUDA alone
+3 more records
Product overview1 text field

Galectin Therapeutics is a biotechnology company developing novel therapies targeting galectin proteins for chronic liver disease and cancer. The company's lead product is belapectin (GR-MD-02), a proprietary carbohydrate-based galectin-3 inhibitor. The core product portfolio centers on belapectin's development for MASH cirrhosis (NAVIGATE clinical trial program), with additional programs in cancer immunotherapy (combining with KEYTRUDA and Yervoy), psoriasis, and atopic dermatitis. Discovery collaborations focus on developing follow-on galectin inhibitors through partnerships with academic institutions and biotech companies.

Product and service6 records
1Belapectin (GR-MD-02)
CategoryGalectin-3 inhibitor / MASH cirrhosis drug candidate
Description

Proprietary carbohydrate-based galectin-3 inhibitor drug candidate (galactoarabino-rhamnogalacturonan polysaccharide polymer) being developed as a disease-modifying therapy for MASH cirrhosis with portal hypertension, with additional programs in cancer immunotherapy, psoriasis, and atopic dermatitis. Binds galectin-1 and galectin-3 with greater affinity for galectin-3.

2NAVIGATE Clinical Trial Program
CategoryLate-stage clinical development program
Description

International seamless Phase 2b/3 clinical trial evaluating belapectin in MASH cirrhosis patients with clinical signs of portal hypertension at risk of developing esophageal varices. Adapted following FDA feedback so Stage 1 is analyzed as a stand-alone trial, with Phase 3 protocol filing planned for Q3 2026.

3Cancer Immunotherapy Program
CategoryOncology combination immunotherapy program
Description

Investigator-initiated combination immunotherapy clinical trials evaluating belapectin with checkpoint inhibitors (KEYTRUDA/pembrolizumab and Yervoy/ipilimumab) for advanced melanoma and head and neck cancer. Phase 1 trial showed a 50% objective response rate in advanced melanoma with belapectin + KEYTRUDA versus 33% for KEYTRUDA alone.

4Psoriasis Program
CategoryInflammatory skin disease clinical program
Description

Exploratory Phase 2a clinical program of belapectin in patients with moderate to severe plaque psoriasis, demonstrating positive antifibrotic and anti-inflammatory biomarker trends. The company is actively seeking a development partner for this indication.

5Atopic Dermatitis Program
CategoryInflammatory skin disease clinical program
Description

Small open-label investigator-initiated study of belapectin in atopic dermatitis (eczema), demonstrating 64-74% reduction in EASI score after 3-6 doses. The company is seeking a development partner to advance this indication.

6Galectin Sciences Discovery Collaborations
CategoryEarly-stage drug discovery / research collaborations
Description

Drug discovery collaborations through Galectin Sciences with SBH Sciences (Natick, MA) to discover small molecule, non-carbohydrate galectin inhibitors for potential oral therapies, and with the Complex Carbohydrate Research Center at the University of Georgia (Dr. Geert-Jan Boons' laboratory) for new carbohydrate-based galectin-targeting molecules. Also includes collaboration with Kevin Mayo at the University of Minnesota examining chemical interactions of belapectin with the galectin receptor.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Covance serves as the Contract Research Organization (CRO) for the NAVIGATE Phase 2b/3 clinical trial, providing clinical trial management services. Covance is a leading global drug development services company.

2SBH Sciences (Natick, MA)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Galectin Sciences collaboration established with SBH Sciences to discover small molecule, non-carbohydrate molecules that can inhibit galectin molecules for development of oral therapies.

galectintherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative drug discovery program with Dr. Geert-Jan Boons' laboratory focused on discovery of new carbohydrate molecules for therapy of diseases where galectin proteins play a major role, including cancer, and inflammatory and fibrotic disorders.

4Kevin Mayo (University of Minnesota)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Kevin Mayo at the University of Minnesota examining chemical interactions of belapectin (GR-MD-02) and other molecules with the galectin receptor.

galectintherapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Providence Portland Medical Center conducted investigator-initiated clinical trials of belapectin in combination with KEYTRUDA (pembrolizumab) and Yervoy (ipilimumab) for metastatic melanoma and head and neck cancer. Phase 1 trial data showed a 50% objective response rate in advanced melanoma with belapectin + KEYTRUDA. The center filed the IND application and continues to fund and conduct investigator-initiated clinical trials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Madrigal developed Rezdiffra (resmetirom), the first FDA-approved drug for MASH (with moderate-to-advanced fibrosis). Most directly comparable competitor to Galectin Therapeutics, both targeting the MASH disease space with liver-directed therapies; Rezdiffra's approval establishes regulatory precedent and competitive benchmark for belapectin.

TypeDirect peer
Description

Akero is developing efruxifermin (an FGF21 analog) for MASH, including compensated cirrhosis (F4). Comparable clinical-stage MASH peer with a fibrosis/cirrhosis focus, competing for the same patient population and clinical investigators as belapectin's NAVIGATE program.

TypeDirect peer
Description

89bio is developing pegozafermin (FGF21 analog) for MASH including in cirrhotic patients. Direct peer in the MASH cirrhosis treatment landscape with a similarly staged clinical program and similar target physician audience.

TypeDirect peer
Description

Inventiva is developing lanifibranor, a pan-PPAR agonist for MASH. Clinical-stage MASH-focused peer with similar regulatory positioning and competing for partnership and capital in the same disease space.

TypeDirect peer
Description

NGM developed aldafermin (FGF19 analog) for MASH and is pursuing liver disease therapies. Comparable clinical-stage peer in MASH drug development with similar scale and partnership orientation.

TypeDirect peer
Description

Viking is developing VK2809 and other candidates for MASH and metabolic liver disease. Clinical-stage peer competing in the MASH fibrosis/cirrhosis space with similar investor and partnership dynamics.

TypeEmerging player
Description

Terns is developing TERN-501 (THR-β agonist) and combination therapies for MASH. Emerging clinical-stage peer in MASH with an overlapping target indication and similar partnership-driven development model.

TypeDirect peer
Description

Intercept developed obeticholic acid (OCALIVA) for MASH and primary biliary cholangitis. Direct peer in liver disease drug development; while Intercept's lead MASH program faced regulatory setbacks, the company represents a comparable regulatory and clinical development pathway for belapectin.

TypeBroad incumbent
Description

Novo Nordisk's semaglutide (Ozempic/Wegovy) is being studied extensively for MASH and reshaping the treatment landscape. A broad incumbent whose GLP-1 franchise is potentially redefining MASH therapy standards and competitive context for belapectin's commercial positioning.

TypeBroad incumbent
Description

Eli Lilly is developing tirzepatide for MASH and is the dominant incumbent in the metabolic disease space overlapping with MASH cirrhosis patients. Represents the major competitive threat from GLP-1/GIP incumbents to belapectin's addressable market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galectin Therapeutics

MASH cirrhosis biopharmaceuticalsgalectintherapeutics.com

Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin (GR-MD-02), a proprietary galectin-3 inhibitor, primarily for MASH cirrhosis patients at risk of esophageal varices, with exploratory programs in cancer immunotherapy, psoriasis, and atopic dermatitis.

What Galectin Therapeutics does

Galectin Therapeutics is a clinical-stage biopharmaceutical company founded in 2000 and listed on NASDAQ under the ticker GALT, headquartered in Norcross, Georgia (Delaware-incorporated). The company develops novel therapies targeting galectin proteins, with its lead drug candidate belapectin (GR-MD-02) — a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that binds and inhibits galectin-3 — being advanced primarily for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Belapectin is currently being evaluated in the NAVIGATE Phase 2b/3 clinical trial at approximately 130 sites across 12 countries, with Phase 2b results published in Hepatology in May 2026 and FDA alignment on a Phase 3 protocol achieved in June 2026; a Phase 3 protocol filing is planned for Q3 2026. The molecule carries FDA Fast Track designation and is protected by composition-of-matter, methods-of-use, and methods-of-production patents extending through at least 2035.

The company is pre-revenue with no commercialized products and is funded primarily by Chairman Richard E. Uihlein, who has provided approximately $100 million in convertible debt and credit facilities between 2021 and 2025, with the most recent December 2025 facility extending cash runway through at least March 2027. Beyond the MASH cirrhosis lead indication, Galectin Therapeutics runs exploratory programs in cancer immunotherapy (combination trials with KEYTRUDA and Yervoy showing a 50% objective response rate in advanced melanoma versus 33% for KEYTRUDA alone), psoriasis (Phase 2a), and atopic dermatitis, all of which the company intends to out-license. Discovery efforts include Galectin Sciences, a collaboration with SBH Sciences to develop oral small-molecule galectin inhibitors, and academic collaborations with the University of Georgia and University of Minnesota.

Galectin's go-to-market model is enterprise-biopharma: the company runs an international Phase 2b/3 trial via Covance as CRO, pursues FDA regulatory alignment, and intends to seek large-pharma co-development and commercialization partnerships for belapectin upon Phase 3 progression. The addressable market is large — over 115 million people worldwide have MASH, and the MASH treatment market is projected to reach $8.6 billion by 2030 at a 22% CAGR. The company has 11–50 employees, presents at investor and scientific conferences (H.C. Wainwright, AASLD, EASL), and publishes in peer-reviewed journals to support both investor positioning and clinical credibility.

Galectin Therapeutics firmographics

Firmographics
Name
Galectin Therapeutics
Legal name
Galectin Therapeutics Inc.
Website
https://galectintherapeutics.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin (GR-MD-02), a proprietary galectin-3 inhibitor, primarily for MASH cirrhosis patients at risk of esophageal varices, with exploratory programs in cancer immunotherapy, psoriasis, and atopic dermatitis.
Ownership category
akta.pro rank

Galectin Therapeutics industry classification

Industry
Product category
MASH cirrhosis biopharmaceuticals
akta.pro industry
PRIMARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Galectin-3 inhibitors
  • MASH cirrhosis therapeutics
  • Carbohydrate-based drugs
  • Fibrotic disease treatment
  • Cancer immunotherapy combinations

Where Galectin Therapeutics is headquartered

Location

Headquarters

HQ city
Norcross
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Galectin Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development / Future Product Revenue: Pre-revenue clinical stage company. The company is developing belapectin for MASH cirrhosis and cancer immunotherapy. Revenue would be generated through future product sales following regulatory approval. The company also seeks partners as programs advance requiring greater resources.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Galectin Therapeutics product offering

Product offering

Core offering

Galectin Therapeutics is developing belapectin (GR-MD-02), a proprietary carbohydrate-based galectin-3 inhibitor, as a disease-modifying therapy for MASH cirrhosis and portal hypertension. The company runs the NAVIGATE Phase 2b/3 clinical program across approximately 130 sites in 12 countries and pursues additional exploratory programs combining belapectin with checkpoint inhibitors (KEYTRUDA, Yervoy) in advanced melanoma and head and neck cancer, as well as in psoriasis and atopic dermatitis.

Product overview

Galectin Therapeutics is a biotechnology company developing novel therapies targeting galectin proteins for chronic liver disease and cancer. The company's lead product is belapectin (GR-MD-02), a proprietary carbohydrate-based galectin-3 inhibitor. The core product portfolio centers on belapectin's development for MASH cirrhosis (NAVIGATE clinical trial program), with additional programs in cancer immunotherapy (combining with KEYTRUDA and Yervoy), psoriasis, and atopic dermatitis. Discovery collaborations focus on developing follow-on galectin inhibitors through partnerships with academic institutions and biotech companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Belapectin (GR-MD-02) Proprietary carbohydrate-based galectin-3 inhibitor drug candidate (galactoarabino-rhamnogalacturonan polysaccharide polymer) being developed as a disease-modifying therapy for MASH cirrhosis with portal hypertension, with additional programs in cancer immunotherapy, psoriasis, and atopic dermatitis. Binds galectin-1 and galectin-3 with greater affinity for galectin-3.
  • NAVIGATE Clinical Trial Program International seamless Phase 2b/3 clinical trial evaluating belapectin in MASH cirrhosis patients with clinical signs of portal hypertension at risk of developing esophageal varices. Adapted following FDA feedback so Stage 1 is analyzed as a stand-alone trial, with Phase 3 protocol filing planned for Q3 2026.
  • Cancer Immunotherapy Program Investigator-initiated combination immunotherapy clinical trials evaluating belapectin with checkpoint inhibitors (KEYTRUDA/pembrolizumab and Yervoy/ipilimumab) for advanced melanoma and head and neck cancer. Phase 1 trial showed a 50% objective response rate in advanced melanoma with belapectin + KEYTRUDA versus 33% for KEYTRUDA alone.
  • Psoriasis Program Exploratory Phase 2a clinical program of belapectin in patients with moderate to severe plaque psoriasis, demonstrating positive antifibrotic and anti-inflammatory biomarker trends. The company is actively seeking a development partner for this indication.
  • Atopic Dermatitis Program Small open-label investigator-initiated study of belapectin in atopic dermatitis (eczema), demonstrating 64-74% reduction in EASI score after 3-6 doses. The company is seeking a development partner to advance this indication.
  • Galectin Sciences Discovery Collaborations Drug discovery collaborations through Galectin Sciences with SBH Sciences (Natick, MA) to discover small molecule, non-carbohydrate galectin inhibitors for potential oral therapies, and with the Complex Carbohydrate Research Center at the University of Georgia (Dr. Geert-Jan Boons' laboratory) for new carbohydrate-based galectin-targeting molecules. Also includes collaboration with Kevin Mayo at the University of Minnesota examining chemical interactions of belapectin with the galectin receptor.

Quantifiable outcome

  • 50% objective response rate in advanced melanoma with belapectin + KEYTRUDA vs 33% for KEYTRUDA alone
  • +3 more outcomes

Companies that use Galectin Therapeutics

Customer profile

Segments1 record

Ideal customer profiles3 records

Galectin Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Galectin Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • CovancecoreImplementation/ SI/ Consulting PartnerCovance serves as the Contract Research Organization (CRO) for the NAVIGATE Phase 2b/3 clinical trial, providing clinical trial management services. Covance is a leading global drug development services company.
  • SBH Sciences (Natick, MA)minorStrategic or Co-development PartnerGalectin Sciences collaboration established with SBH Sciences to discover small molecule, non-carbohydrate molecules that can inhibit galectin molecules for development of oral therapies.
  • Complex Carbohydrate Research Center, University of GeorgiaminorStrategic or Co-development PartnerCollaborative drug discovery program with Dr. Geert-Jan Boons' laboratory focused on discovery of new carbohydrate molecules for therapy of diseases where galectin proteins play a major role, including cancer, and inflammatory and fibrotic disorders.
  • Kevin Mayo (University of Minnesota)minorStrategic or Co-development PartnerCollaboration with Kevin Mayo at the University of Minnesota examining chemical interactions of belapectin (GR-MD-02) and other molecules with the galectin receptor.
  • Providence Portland Medical Center (Earle A. Chiles Research Institute)coreStrategic or Co-development PartnerProvidence Portland Medical Center conducted investigator-initiated clinical trials of belapectin in combination with KEYTRUDA (pembrolizumab) and Yervoy (ipilimumab) for metastatic melanoma and head and neck cancer. Phase 1 trial data showed a 50% objective response rate in advanced melanoma with belapectin + KEYTRUDA. The center filed the IND application and continues to fund and conduct investigator-initiated clinical trials.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Galectin Therapeutics competitors and assessment

Company assessment

Direct peers

  • Madrigal Pharmaceuticals: Madrigal developed Rezdiffra (resmetirom), the first FDA-approved drug for MASH (with moderate-to-advanced fibrosis). Most directly comparable competitor to Galectin Therapeutics, both targeting the MASH disease space with liver-directed therapies; Rezdiffra's approval establishes regulatory precedent and competitive benchmark for belapectin.
  • Akero Therapeutics: Akero is developing efruxifermin (an FGF21 analog) for MASH, including compensated cirrhosis (F4). Comparable clinical-stage MASH peer with a fibrosis/cirrhosis focus, competing for the same patient population and clinical investigators as belapectin's NAVIGATE program.
  • 89bio: 89bio is developing pegozafermin (FGF21 analog) for MASH including in cirrhotic patients. Direct peer in the MASH cirrhosis treatment landscape with a similarly staged clinical program and similar target physician audience.
  • Inventiva: Inventiva is developing lanifibranor, a pan-PPAR agonist for MASH. Clinical-stage MASH-focused peer with similar regulatory positioning and competing for partnership and capital in the same disease space.
  • NGM Biopharmaceuticals: NGM developed aldafermin (FGF19 analog) for MASH and is pursuing liver disease therapies. Comparable clinical-stage peer in MASH drug development with similar scale and partnership orientation.
  • Viking Therapeutics: Viking is developing VK2809 and other candidates for MASH and metabolic liver disease. Clinical-stage peer competing in the MASH fibrosis/cirrhosis space with similar investor and partnership dynamics.
  • Intercept Pharmaceuticals: Intercept developed obeticholic acid (OCALIVA) for MASH and primary biliary cholangitis. Direct peer in liver disease drug development; while Intercept's lead MASH program faced regulatory setbacks, the company represents a comparable regulatory and clinical development pathway for belapectin.

Emerging players

  • Terns Pharmaceuticals: Terns is developing TERN-501 (THR-β agonist) and combination therapies for MASH. Emerging clinical-stage peer in MASH with an overlapping target indication and similar partnership-driven development model.

Broad incumbents

  • Novo Nordisk: Novo Nordisk's semaglutide (Ozempic/Wegovy) is being studied extensively for MASH and reshaping the treatment landscape. A broad incumbent whose GLP-1 franchise is potentially redefining MASH therapy standards and competitive context for belapectin's commercial positioning.
  • Eli Lilly: Eli Lilly is developing tirzepatide for MASH and is the dominant incumbent in the metabolic disease space overlapping with MASH cirrhosis patients. Represents the major competitive threat from GLP-1/GIP incumbents to belapectin's addressable market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Galectin Therapeutics social profiles

Digital presence

Galectin Therapeutics compliance and trust

Trust signal

Compliance1 record

Galectin Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galectin Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Galectin Therapeutics funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galectin Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galectin Therapeutics

What does Galectin Therapeutics do?

Galectin Therapeutics is developing belapectin (GR-MD-02), a proprietary carbohydrate-based galectin-3 inhibitor, as a disease-modifying therapy for MASH cirrhosis and portal hypertension. The company runs the NAVIGATE Phase 2b/3 clinical program across approximately 130 sites in 12 countries and pursues additional exploratory programs combining belapectin with checkpoint inhibitors (KEYTRUDA, Yervoy) in advanced melanoma and head and neck cancer, as well as in psoriasis and atopic dermatitis.

Is Galectin Therapeutics a public or private company?

Galectin Therapeutics is a public company. It is classified as public and is currently operating.

When was Galectin Therapeutics founded?

Galectin Therapeutics was founded in 2000. It employs 11 to 50 people.

Where is Galectin Therapeutics based?

Galectin Therapeutics is headquartered in Norcross, United States, in the North America region.

How does Galectin Therapeutics make money?

One revenue line is on record: drug Development / Future Product Revenue.

Who are Galectin Therapeutics's main competitors?

Direct peers on record are Madrigal Pharmaceuticals, Akero Therapeutics, 89bio, Inventiva, NGM Biopharmaceuticals, Viking Therapeutics and Intercept Pharmaceuticals. Terns Pharmaceuticals is listed as an emerging player. Broad incumbents are Novo Nordisk and Eli Lilly.

Does Galectin Therapeutics have an API?

No public API is recorded for Galectin Therapeutics.

What industry is Galectin Therapeutics in?

Galectin Therapeutics's product category is MASH cirrhosis biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaGalectin Therapeutics GAAP EPS of -$0.04 beats by $0.01Galectin Therapeutics reported Q3 GAAP EPS of -$0.04, beating by $0.01. Cash and equivalents totaled $11.7M as of September 30, 2026, with R&D expenses down 40.1% to $1.6M and net loss narrowing 56.6% to $3.6M.MarketScreenerGalectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Galectin Therapeutics reported a Q3 net loss of $3.53 million, down from $8.18 million a year ago, and a nine-month net loss of $17.69 million, down from $25.34 million. Basic and diluted loss per share from continuing operations were $0.04 and $0.24, respectively, compared to $0.13 and $0.40 a year ago.TradingViewGalectin Therapeutics Reports Q3 2026 Net Loss of $3.6 MillionGalectin Therapeutics reported a Q3 2026 net loss of $3.6 million, down from $8.2 million a year earlier, with cash and equivalents at $11.7 million. The company expects funding to support operations through June 2027. It also submitted a registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis.Stock TitanGalectin Therapeutics submits Phase 3 trial protocol to FDAGalectin Therapeutics reported Q3 2026 results, including a net loss of $3.6 million and $11.7 million in cash. The company submitted its registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis with portal hypertension to the FDA in Q3 2026. Additional data will be presented at the Annual Stockholders' Meeting on December 3, 2026.TradingViewGALT: A $105.8M debt conversion eased liabilities, but funding is expected to last only through June 2027Galectin Therapeutics converted a $105.8M related-party debt balance into shares, easing liabilities. The company's funding is expected to last only through June 2027, despite narrowed losses and advanced NAVIGATE Phase 3 planning after FDA alignment.MarketBeatGalectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - What's Next?Galectin Therapeutics shares crossed above its 200-day moving average on Friday, trading at $3.19. The stock missed Q2 EPS estimates at -$0.14 versus -$0.09, and analysts hold a consensus 'Hold' rating with a $11 target. Institutional investors have recently increased stakes.American Banking and Market NewsGalectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average – What’s Next?Galectin Therapeutics shares crossed above its 200-day moving average on Friday, trading at $3.19. The stock missed Q2 EPS estimates at -$0.14 versus -$0.09, and analysts have an average "Hold" rating with a $11.00 price target. Institutional investors hold 11.68% of the stock.MarketBeatGalectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's WhyGalectin Therapeutics' stock crossed above its 200-day moving average on Thursday, trading at $3.71. The company reported Q2 EPS of -$0.14, missing the -$0.09 consensus, and analysts have a Hold rating with a $11.00 price target.American Banking and Market NewsGalectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average – Here’s WhyGalectin Therapeutics shares crossed above its 200-day moving average on Thursday, trading at $3.71. The stock missed Q2 earnings estimates, and analysts have an average "Hold" rating with a $11.00 price target. Institutional investors hold 11.68% of the stock.Markets DailyGalectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average – Time to Sell?Galectin Therapeutics shares crossed above its 200-day moving average on Wednesday, trading at $3.62. Analysts have an average "Hold" rating with a $11.00 target, and the company missed Q2 EPS estimates at -$0.14. The stock's 50-day moving average is $3.77.